Sight Sciences, Inc. (NASDAQ:SGHT) Receives $8.30 Average Price Target from Analysts

Shares of Sight Sciences, Inc. (NASDAQ:SGHT) have earned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $8.7625.

A number of analysts have weighed in on SGHT shares. William Blair raised shares of Sight Sciences to a “strong-buy” rating in a report on Friday, January 30th. Raymond James Financial set a $9.00 price target on shares of Sight Sciences in a research report on Monday, January 5th. Piper Sandler set a $9.00 price objective on shares of Sight Sciences in a research note on Monday, January 5th. Cantor Fitzgerald set a $8.00 price objective on Sight Sciences in a report on Monday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a report on Monday, December 29th.

Insider Transactions at Sight Sciences

In other news, CFO James Rodberg sold 4,405 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.82, for a total transaction of $34,447.10. Following the transaction, the chief financial officer directly owned 154,440 shares in the company, valued at approximately $1,207,720.80. This trade represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Paul Badawi sold 25,356 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $7.43, for a total transaction of $188,395.08. Following the transaction, the chief executive officer owned 5,937,146 shares in the company, valued at approximately $44,112,994.78. This trade represents a 0.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 99,796 shares of company stock worth $719,722. 28.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Sight Sciences

Large investors have recently bought and sold shares of the business. Americana Partners LLC increased its stake in Sight Sciences by 42.4% in the third quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock valued at $4,231,000 after purchasing an additional 365,901 shares during the period. B Group Inc. grew its holdings in shares of Sight Sciences by 11.6% during the second quarter. B Group Inc. now owns 930,000 shares of the company’s stock worth $3,841,000 after buying an additional 96,400 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Sight Sciences during the second quarter worth about $49,000. Squarepoint Ops LLC acquired a new position in Sight Sciences in the 4th quarter valued at about $323,000. Finally, AQR Capital Management LLC purchased a new stake in Sight Sciences during the 1st quarter valued at approximately $128,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Price Performance

Shares of NASDAQ SGHT opened at $5.26 on Friday. The stock’s 50-day simple moving average is $6.46 and its 200-day simple moving average is $5.76. The firm has a market capitalization of $278.10 million, a PE ratio of -5.84 and a beta of 2.43. Sight Sciences has a fifty-two week low of $2.03 and a fifty-two week high of $9.24. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.